Evolus (NASDAQ:EOLS)‘s stock had its “overweight” rating restated by equities research analysts at Cantor Fitzgerald in a report issued on Tuesday.
A number of other research firms have also recently weighed in on EOLS. HC Wainwright assumed coverage on Evolus in a report on Thursday, February 14th. They issued a “buy” rating and a $37.00 price target for the company. Zacks Investment Research cut Evolus from a “hold” rating to a “sell” rating in a report on Tuesday, February 5th. Mizuho boosted their price target on Evolus from $25.00 to $29.00 and gave the stock a “buy” rating in a report on Tuesday. Finally, Stifel Nicolaus assumed coverage on Evolus in a report on Monday, January 28th. They issued a “buy” rating and a $27.00 price target for the company. One investment analyst has rated the stock with a sell rating and seven have assigned a buy rating to the stock. Evolus presently has a consensus rating of “Buy” and an average target price of $30.29.
Shares of EOLS stock opened at $26.57 on Tuesday. The firm has a market cap of $650.51 million and a P/E ratio of -16.92. Evolus has a 1 year low of $6.75 and a 1 year high of $39.50.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in EOLS. IFP Advisors Inc raised its holdings in shares of Evolus by 239.6% in the fourth quarter. IFP Advisors Inc now owns 8,490 shares of the company’s stock worth $101,000 after acquiring an additional 5,990 shares during the last quarter. Wells Fargo & Company MN raised its holdings in shares of Evolus by 860.3% in the third quarter. Wells Fargo & Company MN now owns 5,944 shares of the company’s stock worth $110,000 after acquiring an additional 5,325 shares during the last quarter. Rhumbline Advisers acquired a new position in shares of Evolus in the fourth quarter worth $129,000. New York State Common Retirement Fund raised its holdings in shares of Evolus by 75.0% in the fourth quarter. New York State Common Retirement Fund now owns 12,600 shares of the company’s stock worth $150,000 after acquiring an additional 5,400 shares during the last quarter. Finally, Janney Montgomery Scott LLC acquired a new position in shares of Evolus in the fourth quarter worth $163,000. 19.82% of the stock is owned by institutional investors.
Evolus Company Profile
Evolus, Inc provides medical aesthetic products for physicians and their patients in the United States. It offers DWP-450, an injectable 900 kilodalton botulinum toxin type A complex designed to address the needs of the facial aesthetics market. The company was founded in 2012 and is headquartered in Irvine, California.
Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.